Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOtorhinolaryngology (ENT)mhn Nasal Valve Repair Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentmhnPolicy CP.MP.210

    Repair of Nasal Valve Compromise

    Customize your policy alerts

    Sign up for mhn Policy CP.MP.210 alerts

    Get alerted when Policy CP.MP.210 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity guidelines for surgical and procedural repair of nasal valve compromise (NVC) for members of the health plan; defines covered indications, required preconditions, and procedures considered investigational or not supported.

    Policy Summary
    Payermhn
    PolicyRepair of Nasal Valve Compromise
    Policy CodePolicy CP.MP.210
    Change TypeMinor/technical (no material clinical changes)
    Effective Date
    Next Review Date
    Key ActionObtain and document trials of conservative therapy (e.g., nasal cones, external nasal dilator adhesive strips, or a six‑week trial of nasal steroids) and confirm clinical findings such as Cottle maneuver response before requesting authorization for repair.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1Covered CPT code listed
    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CPT codes not supporting coverage
    4Core clinical criteria items required
    3Procedures with insufficient evidence

    Coverage Criteria for Repair of Nasal Valve Compromise

    Medically necessary repair of nasal valve compromise

    Covered when ALL of the following are met:

    I.A Clinical findings: Clinical findings of one or more of: internal valve collapse or compromise of the upper lateral cartilage; OR external nasal valve compromise due to collapse of the lower lateral cartilage.
    I.B Symptom correlation: Complaints of obstructed breathing that resolve with the Cottle maneuver or with lateralization of the upper lateral cartilage from inside the nose using an object (examples: cotton swab, nasal speculum, outpatient nocturnal trial of external stents such as Breathe Right nasal strips, or outpatient nocturnal trial of nasal dilators such as Max‑Air Nose Cones or Sinus Cones).
    I.C Rule out other causes: Other causes of obstructed breathing have been ruled out (examples: sinusitis, allergic rhinitis, nonallergic rhinitis, nasal polyps, adenoid hypertrophy, nasopharyngeal masses, septal deviation, and turbinate hypertrophy).
    I.D Conservative therapy: Symptoms persist despite conservative treatment (examples: nasal cones, external nasal dilator adhesive strips, or a six‑week trial of nasal steroids).

    This policy identifies several procedures for repair of nasal vestibular stenosis that do not have established safety and efficacy and therefore are not supported. Specifically, the policy lists radiofrequency ablation (VivAer®), absorbable lateral wall implants (Latera®), and nasal valve suspension surgery as procedures with insufficient evidence to be considered standard care for nasal valve compromise. The VivAer procedure is an office‑based, low‑dose radiofrequency technique intended to remodel intranasal soft tissues by creating controlled coagulation lesions that stiffen tissue as they heal, but available studies are limited in quality and do not clearly demonstrate objective improvements in nasal airflow. The Latera implant is an absorbable PLLA‑PDLA lateral wall support placed endonasally and designed to be replaced by a fibrous matrix over about 12–18 months; however, its safety and long‑term effectiveness remain inadequately established in the evidence base. Due to these limitations, the policy treats these approaches as investigational for repair of nasal vestibular stenosis.

    Coverage is limited to procedures meeting the policy’s medical necessity criteria; procedures billed with CPT 30468 or 30469 are listed as not supporting coverage. CPT 30468 describes repair with subcutaneous/submucosal lateral wall implant(s) and corresponds to absorbable implant approaches such as Latera, while CPT 30469 describes low‑energy, temperature‑controlled radiofrequency subcutaneous/submucosal remodeling, corresponding to procedures like VivAer. The policy explicitly states that VivAer, absorbable implants, and nasal valve suspension surgery lack sufficient established safety and efficacy for repair of nasal vestibular stenosis and thus are not supported for coverage under this policy.

    CPT Codes and Coding Guidance

    CPT Codes That Support Coverage CriteriaCPTCovered
    30465Repair of nasal vestibular stenosis (e.g., spreader grafting, lateral nasal wall reconstruction)
    CPT Codes That Do Not Support Coverage CriteriaCPTNot Covered
    30468Repair of nasal valve collapse with subcutaneous/submucosal lateral wall implant(s).
    30469Repair of nasal valve collapse with low energy, temperature-controlled (i.e., radiofrequency) subcutaneous/submucosal remodeling

    Provider Requirements and Prior Authorization

    Prior Authorization

    Prior Authorization and Coding

    Prior authorization required for repair of nasal vestibular stenosis when coverage criteria are met. Ensure the request is coded to the supporting CPT and includes required clinical documentation (see documentation callout).

    • Submit prior authorization referencing CPT 30465 when clinical criteria for repair of nasal vestibular stenosis are satisfied.
    • Include clinical findings (internal or external valve collapse), response to Cottle maneuver or lateralization testing, and documentation of a trial of conservative therapy.
    Step Therapy

    Conservative Therapy Required

    A documented trial of conservative therapies is required and must be included with the prior authorization request. Examples of acceptable conservative treatments are provided below; duration and response should be noted.

    • Trial of nasal cones (e.g., Max-Air Nose Cones®, Sinus Cones®) or external nasal dilator adhesive strips (e.g., Breathe Right®).

    Background

    Nasal valve compromise (NVC) is a structural narrowing of the nasal passage that can produce symptomatic obstructed breathing. Clinically, NVC may result from internal valve collapse involving the upper lateral cartilage or external nasal valve compromise due to collapse of the lower lateral cartilage. Diagnosis relies on history and focused physical examination maneuvers (for example, the Cottle maneuver or manual lateralization of the upper lateral cartilage), symptom correlation, and exclusion of other causes of obstruction. The policy requires documentation that symptoms correlate with valve findings and persist despite conservative measures before considering surgical repair.

    Definitions

    Nasal valve compromise (NVC) — definition of condition
    DefinitionNasal valve compromise (NVC), also known as nasal valve collapse, is a narrowing of the nasal passageway causing difficult, obstructed breathing due to collapse or weakness of internal or external nasal valve structures.
    Common causesStructural weakness or collapse from injury or trauma, prior nasal surgery, chronic inflammation, congenital defects, or aging.
    Associated conditionsMay present with or be exacerbated by rhinitis, sinusitis, septal deviation, or adenoid hypertrophy.
    Typical symptomsDifficulty inhaling through the nose, sensation of congestion, stuffiness or blockage, nasal bleeding, and snoring.
    VivAer (Aerin) procedure — definition / description
    Procedure description
    Policy Summary
    Payermhn
    PolicyRepair of Nasal Valve Compromise
    Policy CodePolicy CP.MP.210
    Change TypeMinor/technical (no material clinical changes)
    Effective Date
    Next Review Date
    Key ActionObtain and document trials of conservative therapy (e.g., nasal cones, external nasal dilator adhesive strips, or a six‑week trial of nasal steroids) and confirm clinical findings such as Cottle maneuver response before requesting authorization for repair.
    SourceLink
    On This Page
    Coverage Criteria for Repair of Nasal Valve CompromiseCPT Codes and Coding GuidanceProvider Requirements and Prior AuthorizationBackgroundDefinitions
  1. Outpatient nocturnal trial of external stents or nasal dilators and/or a six-week trial of intranasal corticosteroids.
  2. Document duration and patient response to conservative measures in the chart and with the authorization request.
  3. Documentation Required

    Required Clinical Documentation

    Include objective and procedural findings to support medical necessity. At a minimum, document the type of valve compromise, results of Cottle maneuver or lateralization testing, and details of conservative therapy tried.

    • Document internal valve collapse or compromise of the upper lateral cartilage, or external valve compromise from lower lateral cartilage collapse.
    • Record positive response to the Cottle maneuver, Bachman’s maneuver, or lateralization testing (e.g., improved nasal airflow with manual lateralization or instrument simulation).
    • Include NOSE score, nasal endoscopy or anterior rhinoscopy findings, and results of any nasal decongestant testing or objective airflow measures when available.
    Denial Risk

    Unsupported CPT Codes — Denial Risk

    Do not submit requests for repair of nasal valve compromise under CPT codes that do not support coverage; such requests may be denied.

    • CPT 30468 (repair with subcutaneous/submucosal lateral wall implant[s]) is not a covered code for this indication.
    • CPT 30469 (low energy/temperature-controlled radiofrequency subcutaneous/submucosal remodeling, e.g., VivAer®) is not supported and may be denied.
    The Aerin VivAer procedure is a non‑invasive, office‑based treatment that uses low‑dose radiofrequency (RF) energy to modify intranasal soft tissues with the intent of improving airflow in patients with nasal valve collapse.
    Mechanism of actionThe system maintains a target temperature while sparing surrounding mucosa, creates coagulation lesions that heal with tissue retraction and stiffening to reduce obstruction and airflow resistance.
    Device componentsConsists of a console and two styluses (one for nasal airway obstruction and one for chronic rhinitis).
    Evidence summaryClinical studies reviewed provide minimal support; studies suggest safety and possible patient‑reported symptom improvement but limited objective evidence and no comparisons to active treatments.
    Latera absorbable implant — definition / description
    Device descriptionLatera is an absorbable lateral wall nasal implant composed of a PLLA‑PDLA copolymer placed endonasally to support upper and lower lateral wall cartilage.
    Placement and anesthesiaPlaced via an endonasal access point using a 16‑gauge cannula, typically under general anesthesia.
    Duration and biologic responseOver ~12 months the implant becomes enveloped by fibrous tissue; by ~18 months the implant is absorbed and replaced with a fibrous collagen matrix that provides continued support.
    System componentsIncludes the absorbable implant, delivery device, and an implant positioning guide as an external visual planning aid prior to placement.